Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 42Y93 | — |
administration of Kinrix to a 3 year old patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 3-year-old male patient who received DTPa-IPV (Kinrix) (batch number 42Y93, expiry date 05-JUN-2026) for prophylaxis. On 01-APR-2025, the patient received the 1st dose of Kinrix. On 01-APR-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: administration of Kinrix to a 3 year old patient). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 01-APR-2025 The clinic manager reported that they had a patient on the day of reporting and he was a 3 year old, little boy and they gave him Kinrix the IPV and DTAP which led to, inappropriate age at vaccine administration. The reporter stated that they know the vaccine was recommended for 4 year and above so, they just wanted to get the recommendations on that.